Phenotypic transformation of liver sinusoidal endothelial cells is one of the most important stages of liver metastasis progression. The miRNA effects on liver sinusoidal endothelial cells during liver metastasis have not yet been studied. Herein, whole genome analysis of miRNA expression in these cells during colorectal liver metastasis revealed repressed expression of microRNA-20a. Importantly, downregulation of miR-20a occurs in parallel with upregulation of its known protein targets. To restore normal miR-20a levels in liver sinusoidal endothelial cells, we developed chondroitin sulfate-sorbitan ester nanoparticles conjugated with miR-20a in a delivery system that specifically targets liver sinusoidal endothelial cells. The restoration of normal mir-20a levels in these cells induced downregulation of the expression of its protein targets, and this also resulted in a reduction of in vitro LSEC migration and a reduction of in vivo activation and tumor-infiltrating capacity and ability of the tumor decreased by~80% in a murine liver metastasis model.
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are trapped in the sinusoids, they migrate into the tissue parenchyma and grow, thus initiating metastasis. Then, liver cells that are in proximity of tumor undergo deep phenotype changes, 6 which include phenotypic transformation of liver sinusoidal endothelial cells (LSECs), one of the most important events in liver metastasis. 7 LSECs from the fenestrated capillaries of hepatic sinusoids are the first hepatic cell line that interacts with metastatic cells. Upon such interaction, LSECs activate the production of proinflammatory chemokines that generate a favorable environment for tumor growth. 8 One unexplored potential mechanism of LSEC activation is an alteration in cellular epigenetic regulators, in particular microRNAs (miRNAs). miRNAs are small double-stranded RNA molecules comprising 18-22 nucleotides that negatively regulate protein expression by targeting complementary messenger RNAs (mRNAs). 9 The importance of miRNAs has been described in a great variety of physiological processes, such as development 10 and derivation of stem cells, including hepatic cells, 11 as well as in diseases such as cancer 12 and neurodegeneration. 13 In cancer, miRNAs have been shown to play important roles in malignancy processes, which are sometimes associated with their overexpression 14 and other times with their downregulation. 15 Among their broad range of features, there is one feature that makes them especially interesting as therapeutic candidates: their multitarget capacity. As binding to the mRNA does not necessarily require 100% complementarity, a single miRNA can bind to many different mRNAs, thus simultaneously blocking protein translation of multiple targets. 16, 17 This also entails the possibility of side effects that could emerge if miRNA were to be delivered indiscriminately throughout the body. Herein, we shed light on the physiological significance of miRNA deregulation in LSECs and on the potential therapeutic applications derived from a careful choice of miRNA delivery system. In this regard, it is of key importance to guide miRNAs to the specific target cells we want to treat. miRNA instability in serum along with its inability to cross biological membranes makes it necessary to incorporate them into delivery systems to enhance protection and specific cell-targeting. In this way, nanocarriers have emerged as a promising miRNA delivery tool. 18 Thus, we have recently developed and patented sorbitan ester-based nanoparticles and provided an in vivo proof of concept regarding their safety and efficacy for gene therapy. 19, 20 Here, we developed chondroitin sulfatefunctionalized nanoparticles (SP-OA-CS), and we tested them by loading them with specific miRNA for delivery to LSECs in an attempt to explore their therapeutic potential against liver metastasis progression.
Materials and Methods

Animals
Balb/c mice (6-to 8-week-old males) were obtained from Charles River Laboratories Spain S.A. (Barcelona, Spain). All the procedures were approved by the Ethical Committee for Animal Experimentation (CEEA) of the University of the Basque Country (EHU/UPV) in accordance with institutional, national and international guidelines regarding the protection and care of animal use for scientific purposes. Mice were kept in the animal facility of EHU/UPV and had access to standard chow and water ad libitum.
Colorectal cancer cells
Murine colorectal cancer C26 cells (ATCC, Manassas, VA) syngeneic with Balb/c mice were used. The cells were grown under standard conditions in RPMI medium (Sigma-Aldrich; St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), streptomycin (100 mg/ml) and amphotericin B (0.25 mg/ml), all purchased from Life technologies, Carlsbad, CA.
Control and tumor-activated LSECs culture
Control and tumor activated primary cultures of LSECs were isolated form livers with colorectal cancer metastasis or from healthy ones. To do so, Balb/c mice were anesthetized with isofluorano and small cut done in their left broadside. Then, 50 ml for each mice of C26 colon carcinoma cells were inoculated in the spleen at 2 3 10 6 cells/ml concentration and the peritoneum and skin were sutured. The control mice were inoculated with PBS 13 buffer. Fourteen days later, all mice were sacrificed and the tumor activated LSECs and control LSECs were isolated by differential centrifugation. To do so, mice were perfused with collagenase P from Clostridium histolyticum (SigmaAldrich; St. Louis, MO) through cava vein. The obtained cell suspension was twice centrifuged resulting in a parenchymal (PC)-enriched pellet and a non-PC-enriched supernatant.
What's new?
In liver metastasis, liver sinusoidal endothelial cells (LSECs) are among the first cell types to interact with incoming tumor cells, resulting in LSEC activation and transformation. Little is known, however, about the mechanisms driving this process. This study shows that the microRNA miR-20a is downregulated in tumor-colonized LSECs and that its restoration via exogenous delivery can reverse tumor-associated increases in LSEC migratory capacity. In mice, delivery of miR-20a via chondroitin sulfate-functionalized nanoparticles further resulted in decreased liver metastasis progression and reduced activation of tumor-infiltrated LSECs. The findings provide insight into a novel and potentially valuable therapeutic strategy for liver metastasis.
Then, the non-PC-enriched supernatant was layered on Percoll gradients (25% on top of 50%) to obtain LSEC. After a centrifugation, the interphase between the two density cushions was recollected with purified non-PC- miRNA microarray data validation with miRNA RT-qPCR
The microarray data of three of the most downregulated miRNAs (miR-20a, miR-29 and miR-93) were validated with real-time PCR (RT-qPCR) using a miRCURY LNA TM Universal RT microRNA PCR system (Exiqon, Denmark), following the manufacturer's instructions. Then, 50 ng of total RNA was used for cDNA synthesis using a Universal cDNA synthesis kit II (Exiqon, Denmark). cDNA was amplified in triplicate in a 7900 HT Fast Real Time System (Life Technologies, USA) using microRNA LNA primer sets for the specified miRNAs (Exiqon, Denmark) and ExiLENT SYBR V R Green master mix (Exiqon, Denmark). The expression of miRNAs was normalized to the SNORD68 control gene, and the relative expression was calculated with the 2-DDCt method. 21 Quantitative mass spectrometric analysis of liver sinusoidal endothelial cells Isolated tumor-activated LSECs and control LSECs were independently processed for mass spectrometric analysis as previously described. 22 Briefly, samples were shortly separated in a polyacrylamide gel, and proteins were reduced with dithiothreitol, alkylated with iodoacetamide and digested with trypsin. After extraction, the peptides were finally resuspended in 0.1% trifluoroacetic acid. Approximately 500 ng of peptides were subsequently separated on an Ultimate 3000 rapid separation liquid chromatography system (Thermo Fisher Scientific, Dreieich, Germany) and analysed on an Orbitrap Elite (Thermo Fisher Scientific, Dreieich, Germany) hybrid mass spectrometer (supplemental methods).
Preparation and characterization of control SP-OA-CS, SP-OA-CS associated with pEGFP and SP-OA-CS associated with miRNA
For construction of the nanoparticles, a solution of sorbitan monooleate (Span 80, SP) and oleylamine (OA) (SigmaAldrich; St. Louis, MO) was prepared in ethanol at a concentration of 6.6 and 0.33 mg/ml, respectively. Then, this organic phase was added under magnetic stirring to an aqueous phase containing chondroitin sulfate (CS) (Calbiochem, USA) at a concentration of 0.125 mg/ml in a volume ratio of 1:2, respectively. Ethanol was removed under reduced pressure on a rotary evaporator. For the encapsulation of genetic material, this was included in the aqueous phase during the construction of the nanoparticles at concentrations of 33.3 lg/ml for enhanced green fluorescent protein plasmid (pEGFP) (Elim Biopharmaceutics, USA) and 8.33 lg/ml and 16.7 lg/ml for miRNA (miR-20 or miR-control) (Exiqon, Denmark). The final formulations obtained were 200 lg/ml pEGFP-loaded NPs, 50 and 100 lg/ml miRNA-loaded NPs. Formulations were administered in a 5% glucose solution for the in vivo studies. The efficiency of the association of the plasmid DNA and the miRNAs was determined by agarose gel electrophoresis. The morphology of the nanoparticles was examined with transmission electron microscopy (CM 12 Philips, Eindhoven, The Netherlands) after staining with 2% w/v phosphotungstic acid solution. For this purpose, the samples were placed on copper grids (400 mesh) coated with a Formvar
Cancer Therapy and Prevention Figure 1 . The miRNA expression fingerprint of control and tumor-activated LSECs. (a) Experimental design: two groups of mice were inoculated with C26 murine colon cancer cells and with PBS (Control). After 15 days, the mice were perfused and after Percoll V R gradient centrifugation, the LSECs were isolated and miRNA expression microarrays of both cultures were performed. (b) The purity of the LSEC culture was tested by inmunocytochemical analysis. The cells were stained to detect CD146 expression, cell culture purity was analyzed using Image J, and the result indicated a purity of up to 91%. At the same time the cultures were analyzed using contrast phase microscopy to detect hepatic stellate cells by morphology. 
In vivo validation of nanoparticle-specific targeting to LSECs
To confirm the specific targeting of the SP-OA-CS nanoparticles associated with pEGFP to LSECs, Balb/c mice were systemically inoculated via the tail vein with nanoparticles, and after 48 hr, the mice were sacrificed by cervical dislocation. The livers were collected and frozen, and different sections at different levels of each organ were prepared with a cryostat. Finally, the nanoparticle green fluorescence in the sections was analyzed using fluorescence microscopy (Zeiss Axioskope).
Western blot analysis of LESCs activated with tumorconditioned medium
Western blotting analysis was performed with tumoractivated LSECs and tumor-activated LSECs cultured with exogenous miR20a. In brief, LSEC cultures were lysed with RIPA buffer, separated through 8% SDS-PAGE electrophoresis and blotted onto a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA). E2 transcription factor 1 (E2F1) (Santa Cruz Biotechnology, Dallas, TX) and Rho GTPase activating protein (ARHGAP1) (Abcam, Cambridge, UK) (1:1000) were detected using horseradish peroxidaseconjugated protein A (1:5,000) (Sigma-Aldrich; St. Louis, MO). The bands were visualized using a Super Signal Femto Substrate kit (Pierce Chemical Co, Rockford, IL). GAPDH was used as a protein loading control.
Migration of tumor-activated LSECs
A tumor-activated LSEC migration assay was performed on modified Boyden chambers. Briefly, LSECs were cultured onto an 8 mm-diameter pore membrane (Greiner Bio-One, La Jolla, CA) precoated with collagen type I 10 mg/ml (Sigma-Aldrich; St. Louis, MO) at a concentration of 2 3 10 5 cells/ml. Then, cells were allowed to migrate for 24 hr in the presence of different treatments. Migrated cells were quantified after 4% formalin fixation and crystal violet staining (Sigma-Aldrich, St. Louis, MO). The results were calculated from three independent experiments, and data were expressed as the mean of total migrated cells per membrane.
In vivo colorectal cancer liver metastasis development and histological liver tissue analysis
To develop an experimental colorectal cancer liver metastasis model, Balb/c mice were anesthetized with isoflurane (Esteve, Spain), and a small cut was made in their left side. Then, the spleen was exposed to perform an intrasplenic inoculation of 50 ml of C26 colon carcinoma cells at a concentration of 2 3 10 6 cells/ml for each mouse. The animals were divided into 5 groups, and the treatments were performed every 3 days from the day of the inoculation of cancer cells. Finally, the livers were embedded in paraffin and frozen for histological analyses. To quantify the occupied tumor area, consecutive 7-mm sections were cut with 500 mm between them in paraffin-embedded livers. Then, hematoxylin and eosin staining was performed, and the tumor area was quantified using ImageJ Software. In addition, to analyze the potentially activated infiltrating LSECs in the metastasized area, immunostaining with 1:100 dilution of anti-CD31 monoclonal antibody was performed (BD Pharmingen, USA), followed by the appropriate secondary fluorescent Alexa 594 (1:1000) antibody. Images were quantified using the AnalySIS V3.2 program (Olympus Software Imagine Solutions GMBH, Munster, Germany). The results are expressed as a percentage of specifically colored tissue area relative to the entire analyzed area.
Results
The purity of LSEC primary culture is higher than 91%
The isolated control and tumor-activated LSEC purity was confirmed by an immunostaining assay as described in materials and methods (Fig. 1a) . More than 89% of the cells in the LSEC cultures were positive for the CD146 marker (Fig. 1b) . Two hours after isolation, cultures were analyzed under contrast phase microscopy to discard hepatic stellate cells contamination. The cells showed endothelial cells morphology and scarcely appeared retinoic acid containing cells. These cells were used to run a microarray analysis to detect which miRNAs were deregulated in LSECs when livers were colonized by tumor cells compared with control livers.
miRNA microarray assay reveals changes in miRNA expression between tumor activated LSECs and control LSECs A 16 k microarray was run to detect changes in miRNA expression in LSECs obtained from tumor-colonized and control livers. The global analysis of the whole genome miRNA expression revealed that tumor-colonized LSECs and healthy LSECs have a very specific miRNA expression fingerprint, distinct both in the principal component analysis (PCA) shown in Figure 1d and in the hierarchical clustering (Fig. 1e) . We searched for the most deregulated miRNAs (Figs. 1f and 1g ) and found 33 miRNAs that were significantly (p < 0.005) downregulated in tumor-colonized LSEC samples relative to noncolonized samples (Fig. 1b) . miR-20a, miR-29 and miR-93 were among the most significantly downregulated miRNAs (Figs. 1f and 1g ). These miRNAs were validated using qPCR. Among these, the most deregulated was miR-20a, with a negative fold change of >7 (Fig. 1h ).
E2F1 and ARHGAP1 miR-20a target proteins were downregulated in LSECs colonized by the tumor relative to healthy LSECs
We used the miRBASE database (www.mirbase.org) to predict 713 proteins as possible miR-20a targets. In parallel, in a proteomic study, we identified 174 proteins that were upregulated in tumor-activated LSECs compared with control LSECs. When both studies were compared, 5 coincidentally expressed proteins were found: E2F1, JAK1, ARHGAP1, ACSL4 and DECR1 (Fig. 2a) .
To validate these results, a Western blot analysis was performed with LSECs under different treatments. Under control conditions, E2F1 and ARHGAP1 showed low expression. However, after LSEC activation with the tumor, both E2F1 and ARHGAP1 were largely upregulated. Additionally, when cells were transfected in vitro with miR-20a, the protein expression was reduced in both cases to basal levels (Fig. 2b) .
Increased migratory capacity of LSECs activated by tumor signals is prevented by miR-20a
To verify whether miR-20a ablation in LSECs from tumorcolonized livers had any consequence on the physiological behavior of these cells, we cultured them in collagen-coated 8-lm pore inserts to measure their migration capacity. Tumor-activated LSECs were treated with miR-20a, with miR-control or with the unloaded transfection vehicle Myrus V R . We found that LSEC migration capacity increased approximately twofold when cells were activated by the tumor, but this was reversed almost to basal levels when cells were transfected with exogenous miR-20a (p < 0.05). Therefore, restoring cellular miR-20a expression in LSECs was sufficient to prevent the increased migratory capacity associated with tumor-induced activation (Fig. 2c) .
Sorbitan ester nanoparticles encapsulate both DNA and miRNA forms of nucleic acids
The nanoparticles (SP-OA-CS) were developed through a self-assembly process, as previously described 23 (Fig. 3a) . The genetic material (plasmid EGFP or miR-20a) inserted into nanoparticles was evaluated using electrophoresis. As shown in Figure 3c , migration of the nucleic acids into the gel was prevented by their association with the nanoparticles in the finally selected formulations (lines 2 and 4), and no free genetic material was observed in these formulations. Blank nanoparticles (with no genetic material incorporated) and those nanoparticles with associated pEGFP and miR-20a had nanometric sizes of 133 nm, 143 nm and 143 nm and negative surface charges of 238, 236 and 233 mV, respectively (Table 1 and Fig. 3b ). The morphology of the nanosystems was observed using transmission electron microscopy (TEM). TEM images confirmed the nanometric size of the formulations (Fig. 3d) .
To demonstrate the cellular uptake and transfection ability of SP-OA-CS nanoparticles by LSECs, a plasmid DNA encoding GFP was incorporated during their preparation. GFP expression was evaluated 24 hr post-transfection using fluorescence microscopy. At this experimental time, LSECs expressed GFP, as shown in Figures 4a and 4b , indicating successful nanoparticle internalization and plasmid delivery. To evaluate whether our nanoparticle-based delivery system could be effective in targeting LSECs in vivo, SP-OA-CS containing EGFP plasmid were injected systemically into mice. As shown in Figure 4c , the liver sinusoids expressed GFP, indicating successful plasmid delivery. Moreover, sections were immunostained with anti-mannose receptor (Figs. 4e and 4f) and F4/80 antibodies (Fig. 4d) . As shown in Figure  4f , the GFP-positive cells were endothelial cells. The miR-20a fluorescence signal was detected in LSECs (Figures 4g and  4h) when the mice were injected with nanoparticles associated with miRNA. Meanwhile, the fluorescent signal was broader when miR-20a was injected in the naked form (Figures 4i and 4j) . 
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Nanoparticle-mediated delivery of miR-20 to LSECs decreased liver metastasis progression and reduced activated LSEC recruitment into metastatic foci
A murine liver metastasis model was developed to study the potential therapeutic effect of the LSEC-targeted nanoparticles containing miR-20a as previously described (Fig. 5a ).
As shown in Figure 5b , the tumor-occupied area decreased by 20% when mice were treated with naked miR-20a. Additionally, the tumor-occupied area was decreased by almost 80% when the animals were treated with SP-OA-CS associated with miR-20a. Moreover, quantification of the activated LSECs in the tumor foci by CD31 immunostaining showed a reduction of 70% in tumor-infiltrated LSECs in the livers of mice treated with SP-OA-CS associated with miR-20a compared with control samples (Fig. 5c ).
Discussion
The importance of miRNAs as key regulators in embryonic development and in the maintenance of physiological homeostasis and different diseases has been broadly described. 24 In this study, we aimed to analyze the function of miRNAs in LSEC activation during liver metastasis progression.
In an attempt to explore the mechanisms underlying prometastatic LSEC activation, we developed a colorectal cancer liver metastasis model and isolated LSECs to evaluate the deregulation of miRNA expression relative to normal healthy conditions. After microarray data analysis and validation by quantitative PCR, miR-20a was the most altered. miR-20a has been previously described as a miRNA that is deregulated in many different tumors, such as lung cancer, 25 cervical cancer 26 and thyroid cancer, 27 and it has also been described as an essential component of embryonic development and a regulator of Wnt signaling. 28 miRNAs repress protein expression through complementary matching with target mRNA using different mechanisms. 29 During liver metastasis progression, the LSEC phenotypic changes to generate a prometastatic cell are the result of a change in the cellular protein expression pattern. We hypothesized that some proteins that facilitate this metastasis-supporting phenotype of LSECs are blocked by miRNA naturally expressed in healthy conditions and that downregulation of these miRNAs during the activation of LSECs leads to prometastatic protein overexpression. Thus, in parallel with the miRNA study, we performed a proteomic study of tumor-colonized and healthy LSECs. In addition, the potential targets of miR-20 were searched using the microRNA database miRBASE, yielding a list of 713 protein target candidates. Specifically, five of them were validated by our proteomic study as overexpressed in tumor-colonized LSECs: JAK1, ARHGAP1, ACSL4, DECR1 and E2F1. In addition, two of them, ARHGAP1 and E2F1, showed direct correlation between tumor-activated expression and miR-20a. ARHGAP1 is a Rho GTPase activating protein that is also related to angiogenic processes in metastasis. 30 E2F1 is a transcription factor that can activate different downstream genes involved in many biological processes, such as those involved in the cell cycle during G 1 -S-phase transition, DNA synthesis and replication, DNA repair, apoptosis, autophagy, self-renewal, development and differentiation.
31 E2F1 is one of the known key proteins that can modulate cell fate and activation capacity. It has been reported that this protein acts as a crucial protein during mesenchymal cell differentiation to endothelial cells 32 and lymphatic cell differentiation and proliferation.
33 E2F1 has not only been described as an endothelial cell differentiation and proliferation element but also as an angiogenesis regulator. 34 Thus, E2F1 overexpression could be part of the molecular mechanism involved in LSEC prometastatic activation.
In this study, E2F1 and ARHGAP1 expression levels were upregulated in tumor-activated LSECs. Importantly, the expression of both proteins decreased after exogenous miR20a administration. In these conditions, in vitro LSEC migration decreased and in vivo endothelial cell activation was also reduced. The interaction between miR20a and E2F1 had been previously described in a myoblast differentiation model. 35 We show that the number of CD31-positive LSECs was significantly lower in the in vivo metastasis model after miR-20a The different treatments were injected into mice every 3 days. Group I mice received PBS as a control treatment; group II mice received miR-20a-loaded nanoparticles; group III mice received miR-20a; group IV mice were treated with nonspecific miRNA (Control)-loaded nanoparticles; and group V mice were treated with empty nanoparticles. After 21 days, the animals were sacrificed, and the livers were removed for histological analysis. (b) Liver sections were stained with hematoxylin-eosin, and the tumor size was determined as the area of occupied surface relative to the liver surface in a field under the microscope at 43 magnification. Statistically significant (p < 0.05) differences between the control group and the group treated with miR-20a without any vehicle and between the control group and the group treated with chondroitin sulfate-coated span nanoparticles loaded with miR-20a are marked with *. Statistically significant (p < 0.05) differences between the group treated with miR-20a without any vehicle and the group treated with chondroitin sulfate-coated span nanoparticle loaded with miR-20a are marked with 1. (c) Tumor foci from different groups of metastasis model mice were analyzed to determine the number of active LSECs in the tumors to evaluate the tumor supporting role of the cells. Statistically significant (p < 0.05) differences between the control group and the group treated with miR-20a without any vehicle and between the control group and the group treated with chondroitin sulfate-coated span nanoparticles loaded with miR-20a are marked with*. Statistically significant (p < 0.05) differences between the group treated with miR20a without any vehicle and the group treated with chondroitin sulfate-coated span nanoparticle loaded with miR-20a are marked with 1. [Color figure can be viewed at wileyonlinelibrary.com] treatment. This indicates that restoration of miR-20a levels in activated LSECs could be sufficient to decrease neoangiogenesis and vascular support to tumors.
Considering the multitarget capacity of miRNAs and the different effects that may be produced depending on the organ they are targeting, it was mandatory to design a system that could specifically deliver the miR-20a to LSECs. Overall, our previously developed nanoparticle, based on sorbitan esters, met the essential requirements as suitable nucleotidebased bioactive molecules, as previously described. 36 In some of our previous patents, we collected in vivo proofs of concept of the safety and efficacy of such nanosystems for the development of nanomedicines based on delicate bioactive molecules, including gene therapy nanomedicines. 37 On the basis of previous data, we decided to modify the surface of these nanoparticles with the polysaccharide chondroitin sulfate (CS) as a functional moiety for achieving nanoparticlemediated miRNA targeted delivery to LSECs, thus producing span, oleylamine and chondroitin sulfate-based nanoparticles (SP-OA-CS). This biocompatible and biodegradable material was chosen for its high affinity for hyaluronan receptors and mannose receptors, both of which are expressed on LSECs. 38, 39 The hyaluronic acid receptor for endocytosis (HARE, also known as Stabilin-2) is the main scavenger receptor for hyaluronic acid and chondroitin sulfate clearance. 40 It is mainly expressed on the sinusoidal endothelial cells of the lymph nodes, liver and spleen. 41 As a first step in the evaluation of the initial nanoparticle prototype, we tried to corroborate the LSEC targeting ability both in vitro and in vivo. For this purpose, we incorporated the plasmid EGFP into the nanoparticles, as the expression of the GFP protein and subsequent fluorescent labelling will be produced at the targeted cells, thus allowing us to not only corroborate the targeting ability but also the transfection efficacy in vitro and in vivo. In this respect, we should consider that one of the major limitations of drug delivery nanosystems is their fast uptake by the reticuloendothelial system (RES), which consists of phagocytic cells such as monocytes and macrophages, including liver Kupffer cells, resulting in short circulation half-lives of nanosystems. [42] [43] [44] However, our anionic nanosystems demonstrated in vivo LSEC-specific internalization, avoiding Kupffer cell uptake.
LSECs are one of the most important cell type of the tumor microenvironment supporting metastasis progression. 7, 45 In this work, we tried to restore the normal healthy LSEC phenotype through miRNA delivery, in an attempt to revert pathological changes in the protein expression pattern of LSECS by affecting multiple prometastatic targets simultaneously. This strategy proved largely successful, because the expression of CD31 in livers collected from the in vivo metastasis murine model treated with miR-20a-conjugated nanoparticles revealed a reduction of CD31-positive LSEC infiltration into tumor foci. Moreover, this correlated well with a metastatic tumor-occupied area reduction, and this reduction was also significantly more than the one induced by naked miR-20a. In the same way, proteins such as E2F1 and ARHGAP1, which are related to cell cycle, metabolism, migration and differentiation, were found to be depleted in vitro after miR-20a injection. It is unknown why early activation of LSECs induces miR-20a depletion, and further research is needed to elucidate the full cascade of events that occur after tumor cell adhesion to LSECs. In any case, in the present report, we show that our developed nanosystem is able to specifically deliver miR-20a to LSECs, which could eventually be clinically exploited as a valuable therapeutic strategy to inhibit the progression of liver metastasis. Accordingly, these results corroborate the implication that miR-20a downregulation plays a prometastatic role in LSEC differentiation, and the supporting role of LSECs in the metastatic liver tumor microenvironment.
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